Shweta Motiwala, MD
Advanced Heart Failure and Transplant Cardiology · San Francisco, CANPI 1942437470
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $48,825 of the $50,343 with a category attached, or 97.0%. Abbott accounts for 97.4% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2020 at $19,200 and has fallen 93.0% since, to $1,337 in 2025.
Across 57 payments — averaging $883.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$49K
- Cvrx, Inc.$1K
Across 18 payments — averaging $4258.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endotronix, Inc.$48K
- Vifor (international) Ltd.$22K
- Beckman Coulter, Inc.$6K
- Abbott$139
What the payments were for
- Consulting fees$48,82597%
- Travel & lodging$8412%
- Food & beverage$6771%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 51 | $49,031 |
| Cvrx, Inc. | 6 | $1,312 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioMEMS HF System$37,925
- CARDIOMEMS$9,916
- Barostim Neo System$1,289
How this compares
$50,343 in reported general payments places this provider in the 70th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 20 | $22,547 |
| EntrestoSacubitril/Valsartan | 13 | $22,188 |
| FarxigaDapagliflozin Propanediol | 14 | $10,160 |
| Eplerenone | 12 | $1,060 |
| Bumetanide | 14 | $416 |
| Metoprolol Succinate | 18 | $396 |
| Valsartan | 15 | $291 |
| Spironolactone | 43 | $207 |
| Losartan Potassium | 12 | $112 |
| Torsemide | 11 | $82 |
| Levothyroxine Sodium | 13 | $47 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in San Francisco
- Teresa de MarcoSan Francisco$366K
- Liviu KleinSan Francisco$223K
- Marc SimonSan Francisco$114K
- Michael MartynSan Francisco$89K
- Mandar ArasSan Francisco$41K
- Jared HerrSan Francisco$12K
- Michael PhamSan Francisco$9K
- Pooja PrasadSan Francisco$8K
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.